<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref103">
 <mixed-citation publication-type="journal" id="cit103">
  <name>
   <surname>Kumar</surname>
   <given-names>V.</given-names>
  </name>; 
  <name>
   <surname>Shin</surname>
   <given-names>J. S.</given-names>
  </name>; 
  <name>
   <surname>Shie</surname>
   <given-names>J. J.</given-names>
  </name>; 
  <name>
   <surname>Ku</surname>
   <given-names>K. B.</given-names>
  </name>; 
  <name>
   <surname>Kim</surname>
   <given-names>C.</given-names>
  </name>; 
  <name>
   <surname>Go</surname>
   <given-names>Y. Y.</given-names>
  </name>; 
  <name>
   <surname>Huang</surname>
   <given-names>K. F.</given-names>
  </name>; 
  <name>
   <surname>Kim</surname>
   <given-names>M.</given-names>
  </name>; 
  <name>
   <surname>Liang</surname>
   <given-names>P. H.</given-names>
  </name>
  <article-title>Identification and evaluation of potent middle east respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors</article-title>. 
  <source>Antiviral Res.</source>
  <year>2017</year>, 
  <volume>141</volume>, 
  <fpage>101</fpage>â€“
  <lpage>106</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.02.007</pub-id>.
  <pub-id pub-id-type="pmid">28216367</pub-id>
 </mixed-citation>
</ref>
